-
Incannex Receives HREC Approval For Phase 2 Clinical Trial Of CBD-Based Drug For Use In Treatment Of Rheumatoid Arthritis
Thursday, July 13, 2023 - 9:30am | 566Read More...Incannex Healthcare Limited (NASDAQ: IXHL) (ASX:IHL) has received approval from Bellberry Human Research Ethics Committee (‘HREC’) for the lead site, Emeritus Research, Camberwell, Victoria, for its phase 2 clinical trial. The trial will assess the efficacy of IHL-675A, its proprietary...
-
Incannex Starts Phase 2 Clinical Trial Of CBD-Based Drug For Use In Treatment Of Rheumatoid Arthritis
Tuesday, February 28, 2023 - 11:51am | 528Read More...Incannex Healthcare Limited (NASDAQ: IXHL) (ASX:IHL) has commenced a phase 2 clinical trial to assess the safety and efficacy of its proprietary anti-inflammatory combination drug IHL-675A in patients with rheumatoid arthritis (‘RA’). IHL-675A is a proprietary fixed dose combination...
-
Incannex Approved To Commence Phase 1 Clinical Trial Of CBD Based Anti-Inflammatory Drug
Thursday, July 21, 2022 - 9:04am | 599Read More...Incannex Healthcare Limited (NASDAQ: IXHL) (ASX:IHL) has received approval from the Bellberry Human Research Ethics Committee ('HREC') for a phase 1 clinical trial investigating its proprietary multi-use, anti-inflammatory drug IHL-675A. IHL-675A is a combination cannabinoid drug comprising...
